Jonathan Aschoff (Roth MKM) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Jonathan Aschoff's stock ratings?

About 30% of Jonathan's ratings were profitable over a one-year hold, with an average return of -12.8% per rating, measured by 13Foresight from historical prices.

Q: How is Jonathan ranked?

Jonathan Aschoff is ranked #2564 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Jonathan Aschoff

ROTH

Jonathan Aschoff

Roth MKM

Wall Street Analyst

★☆☆☆☆

#2564

on 13Foresight · ranked by our own returns

30%

Success Rate

-12.8%

Average Return

14 of 46 calls profitable · -27.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 30% of Jonathan Aschoff's ratings turned a profit when each position was held for 1 year — averaging -12.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

48 Buy 0 Hold 0 Sell

Jonathan's Stock Coverage 60 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
GOVX GeoVax Labs	May 26, 2026	BUY	Strong Buy +5683.6% avg upside 5 analysts	$10.00 646.25% Upside	-52.7%
PTHS Pelthos Therapeutics	May 15, 2026	BUY	Strong Buy +97.3% avg upside 8 analysts	$55.00 89.60% Upside	-3.4%
BFRI Biofrontera	May 15, 2026	BUY	Strong Buy +507.8% avg upside 2 analysts	$9.00 811.76% Upside	-0.6%
CLNN Clene	May 14, 2026	BUY	Strong Buy +442.4% avg upside 11 analysts	$30.00 399.25% Upside	-3.0%
APVO Aptevo Therapeutics	May 14, 2026	BUY	Strong Buy +163.1% avg upside 4 analysts	$21.00 349.70% Upside	-0.3%
REVB Revelation Biosciences	May 08, 2026	BUY	Strong Buy +1532.6% avg upside 1 analyst	$16.00 1532.63% Upside	·
MDCX Medicus Pharma Ltd	May 07, 2026	BUY	Strong Buy +3069.4% avg upside 4 analysts	$9.00 1867.17% Upside	-2.5%
CLRB Cellectar Biosciences	May 05, 2026	BUY	Strong Buy +2960.9% avg upside 7 analysts	$11.00 294.34% Upside	-22.0%
CELZ Creative Medical Technology Holdings	Apr 28, 2026	BUY	Strong Buy +796.9% avg upside 1 analyst	$20.00 796.91% Upside	·
BRTX BioRestorative Therapies	Apr 02, 2026	BUY	Strong Buy +1853.1% avg upside 3 analysts	$15.00 3562.11% Upside	-27.5%
GTBP GT Biopharma	Mar 02, 2026	BUY	Strong Buy +1942.8% avg upside 3 analysts	$3.00 483.59% Upside	-8.8%
MBRX Moleculin Biotech	Feb 23, 2026	BUY	Strong Buy +603.1% avg upside 5 analysts	$31.00 976.38% Upside	+0.9%
ZVRA Zevra Therapeutics	Jul 22, 2025	BUY	Strong Buy +85.5% avg upside 15 analysts	$21.00 62.89% Upside	+8.9%
OTRKQ Ontrak	Jul 08, 2025	BUY	Buy +21716566.7% avg upside 7 analysts	$3.00 2999900.04% Upside	·
BPTH Bio-Path Holdings	Jun 04, 2025	BUY	Strong Buy +22332.4% avg upside 6 analysts	$2.00 5305.35% Upside	·
TENX Tenax Therapeutics	May 15, 2025	BUY	Strong Buy +213.9% avg upside 8 analysts	$30.00 149.98% Upside	+110.2%
NUWE Nuwellis	May 13, 2025	BUY	Strong Buy +16826.0% avg upside 7 analysts	$11.00 8139.71% Upside	-97.5%
ES:ORY Oryzon Genomics SA	May 12, 2025	BUY	Strong Buy +225.7% avg upside 2 analysts	$12.00 278.06% Upside	·
NVCT Nuvectis Pharma	Oct 28, 2024	BUY	Strong Buy +32.3% avg upside 6 analysts	$20.00 44.69% Upside	-18.0%
BGMS Bio Green Med Solution	Oct 23, 2024	HOLD	Strong Buy +1647.8% avg upside 7 analysts	—	-98.4%
AU:IMU Imugene	Sep 03, 2024	BUY	Strong Buy +457.8% avg upside 2 analysts	$0.59 395.27% Upside	·
GRDX GridAI Technologies	May 21, 2024	BUY	Strong Buy +275.0% avg upside 7 analysts	$36.00 566.64% Upside	-86.2%
DFTX Definium Therapeutics	Mar 07, 2024	BUY	Strong Buy +44.9% avg upside 20 analysts	$36.00 47.02% Upside	-24.1%
HSDT Solana Company	Mar 05, 2024	BUY	Strong Buy +1277.5% avg upside 8 analysts	$24.00 1381.40% Upside	-91.7%
PBLA Panbela Therapeutics	Dec 18, 2023	BUY	Buy +4504404.4% avg upside 3 analysts	$500.00 4504404.43% Upside	·
IMMX Immix Biopharma	Feb 27, 2023	BUY	Strong Buy +105.0% avg upside 8 analysts	$14.00 60.51% Upside	+52.3%
OCGN Ocugen	Jun 15, 2022	BUY	Strong Buy +645.9% avg upside 17 analysts	$8.00 545.15% Upside	-74.2%
AMPE Ampio Pharmaceuticals	Apr 28, 2022	BUY	Buy +9184.6% avg upside 4 analysts	$30.00 16284.55% Upside	-92.6%
BNBX BNB Plus	Oct 25, 2021	BUY	Strong Buy +2256.1% avg upside 5 analysts	$24.00 5852.37% Upside	-70.6%
SEELQ Seelos Therapeutics	Sep 27, 2021	BUY	Buy +46385614.3% avg upside 10 analysts	$8.00 7999899.94% Upside	-56.1%
NTBLQ Notable Labs	Aug 30, 2021	BUY	Buy +809999900.0% avg upside 12 analysts	$7.00 699999900.03% Upside	·
NOVN Novan	Jun 11, 2021	BUY	Buy 6 analysts	$40.00	·
SHLS Shoals Technologies Group	Mar 11, 2021	BUY	Strong Buy +38.1% avg upside 26 analysts	$38.00 264.75% Upside	-48.2%
ARDS Aridis Pharmaceuticals	Nov 22, 2020	BUY	Strong Buy +427319.4% avg upside 5 analysts	$18.00 580545.11% Upside	-66.4%
INO Inovio Pharmaceuticals	Nov 17, 2020	SELL	Buy +808.5% avg upside 19 analysts	$8.00 617.49% Upside	+36.8%
HYPD Hyperion DeFi	Oct 14, 2020	BUY	Strong Buy +143.0% avg upside 8 analysts	$11.00 218.85% Upside	·
INMB Inmune Bio	Jul 14, 2020	BUY	Buy +753.7% avg upside 11 analysts	$26.00 1693.16% Upside	+45.8%
ONCY Oncolytics Biotech	Apr 20, 2020	BUY	Strong Buy +654.5% avg upside 12 analysts	$9.00 837.49% Upside	+115.7%
TRVN Trevena	Sep 15, 2016	BUY	Buy +128278.4% avg upside 11 analysts	$14.00 126026.10% Upside	·
PALI Palisade Bio	Sep 13, 2016	BUY	Strong Buy +1347.1% avg upside 15 analysts	$4.00 113.86% Upside	-67.6%
HRTX Heron Therapeutics	Sep 09, 2016	BUY	Strong Buy +6439.5% avg upside 21 analysts	$55.00 13073.74% Upside	-14.9%
AXSM Axsome Therapeutics	Aug 19, 2016	BUY	Strong Buy -10.6% avg upside 28 analysts	$29.00 88.41% Downside	-33.7%
CTSO Cytosorbents	Aug 10, 2016	BUY	Strong Buy +2600.4% avg upside 13 analysts	$24.00 5375.63% Upside	-4.9%
INCY Incyte	Aug 10, 2016	BUY	Buy +1.0% avg upside 47 analysts	$92.00 6.28% Downside	+46.3%
CLDX Celldex	Aug 09, 2016	BUY	Strong Buy +20.6% avg upside 28 analysts	$16.00 50.63% Downside	-45.9%
SCYX SCYNEXIS	Aug 09, 2016	BUY	Strong Buy +225.1% avg upside 10 analysts	$16.00 295.05% Upside	-20.1%
AKBA Akebia Therapeutics	Aug 09, 2016	BUY	Strong Buy +831.9% avg upside 16 analysts	$26.00 2329.95% Upside	+74.4%
TGTX TG Therapeutics	Aug 09, 2016	BUY	Strong Buy -34.3% avg upside 19 analysts	$28.00 47.44% Downside	·
RMTI Rockwell Med	Aug 09, 2016	SELL	Buy +1445.2% avg upside 11 analysts	$3.00 368.78% Upside	+6.2%
PCRX Pacira Pharmaceuticals	Aug 05, 2016	HOLD	Buy +74.3% avg upside 21 analysts	—	-14.5%
NKTR Nektar Therapeutics	Aug 04, 2016	BUY	Buy +16.6% avg upside 25 analysts	$18.00 70.58% Downside	+14.7%
IPCIQ IntelliPharmaCeutics International	Jul 06, 2016	BUY	Buy +1649999899.9% avg upside 4 analysts	$8.00 799999899.92% Upside	·
REGN Regeneron	Mar 08, 2016	BUY	Strong Buy +26.9% avg upside 57 analysts	$489.00 19.80% Downside	-3.4%
SNGX Soligenix	Nov 12, 2015	BUY	Buy +724.5% avg upside 6 analysts	$5.00 1151.53% Upside	-60.7%
LITS Lite Strategy	Dec 08, 2014	BUY	Buy +1215.4% avg upside 13 analysts	$16.00 1832.86% Upside	·
BMRN BioMarin Pharmaceutical	Oct 24, 2014	HOLD	Strong Buy +72.7% avg upside 52 analysts	—	+28.5%
UTHR United Therapeutics	Feb 26, 2013	HOLD	Buy -19.0% avg upside 26 analysts	—	+72.2%
IMNN Imunon	Jan 17, 2013	SELL	Strong Buy +705.9% avg upside 11 analysts	$1.00 45.11% Downside	+88.0%
ASMB Assembly Biosciences	Jun 29, 2012	BUY	Strong Buy +38.6% avg upside 10 analysts	—	-43.8%
HALO Halozyme	Apr 16, 2012	BUY	Strong Buy -13.7% avg upside 20 analysts	$11.00 84.03% Downside	-32.9%

🔒 55 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Jonathan Aschoff — Frequently Asked Questions

How accurate are Jonathan Aschoff's stock ratings?

Based on the calls 13Foresight could measure, about 30% of Jonathan's ratings were profitable over a one-year hold, with an average return of -12.8% per rating, or -27.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Jonathan ranked on 13Foresight?

Jonathan Aschoff is currently ranked #2564 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Jonathan cover?

Jonathan most recently has ratings on GOVX, PTHS, BFRI, CLNN, APVO, REVB, MDCX, CLRB, CELZ, BRTX, GTBP, MBRX and 48 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!